| INTRODUCTION
Atrial fibrillation (AF) is the most common sustained arrhythmia, and its prevalence of approximately 1% in the Japanese population is steadily increasing due to the country's aging population. [1] [2] [3] Without anticoagulation, AF is associated with a fourfold to fivefold increase in the risk of stroke. 4 as recommended by the guidelines. 6 One of these NOACs, rivaroxaban (BAY59-7939), is a novel, oral, direct factor Xa inhibitor that inhibits thrombin formation via a different mechanism of action than that of warfarin. Rivaroxaban offers benefits over warfarin such as a rapid onset of action, no requirement to conduct monitoring for dose adjustment, and fewer interactions with food and concomitant drugs. 7 In 2012, rivaroxaban In the phase III J-ROCKET AF, rivaroxaban was compared with dose-adjusted warfarin for the prevention of stroke and SE in high- 
| METHODS
This postmarketing surveillance study was approved by the Ministry of Health, Labour, and Welfare (MHLW) and will be carried out in accordance with the standards for Good Post-marketing Study Practice provided by the MHLW in Japan.
| Objectives
The 
| Patient population
Eligible patients comprise men or women with NVAF starting rivaroxaban therapy to reduce the risk of stroke/SE. Contraindications to rivaroxaban therapy were considered according to the Japanese package insert.
| Drug administration
In Japan, rivaroxaban at 15 and 10 mg od is approved for patients with a CrCl of ≥50 and <50 mL/min, respectively. Treating 
| Baseline data
The baseline data collected were as follows. 
| Study outcomes
The primary outcomes are those that allow for assessment and estimation of the safety of rivaroxaban in routine clinical practice, particularly in patients weighing ≤50 kg and those aged ≥75 years.
These outcomes will be recorded as adverse events (AEs) or serious AEs, which will comprise bleeding events (major and nonmajor bleeding events, principal safety outcome) and effectiveness events 
| Statistical analysis plan
Statistical analyses are descriptive, exploratory, and generally limited to frequency tables or summary statistics (eg, mean AE standard deviation or median AE quartile for continuous variables and frequency or percentage for categorical variables), for example, for demographic data. Events of interest are presented as both raw incidence proportions (patients with events/number of treated patients) and incidence rates (eg, patients with events per 100 patient-years).
Each estimate is presented with the corresponding 95% CI. KaplanMeier plots will show the time course up to the first event of interest. Multivariate data analysis is also planned.
| Data management
Data from the XAPASS are captured in electronic CRFs, which comprise three parts. The investigating physician enters and transmits Table S1 .
| CHADS 2 score in age or body weight groups
The CHADS 2 score varied among age-groups ( Figure 3A , Figure S1A ).
More than 50% of <75-year-old patients had a CHADS 2 score of 0-1. More patients aged ≥75 than <75 years had a CHADS 2 score of ≥2, which is partially caused by the fact that an age of ≥75 years is a risk factor for a higher CHADS 2 score. Conversely, the CHADS 2 score tended to gradually increase as body weight decreased (Figure 3B , Figure S1B ). More than 70% of patients with a body weight of <50 kg had a CHADS 2 score of ≥2.
| Age and body weight
Patients with a body weight of ≤50 kg or age of ≥75 years are considered to have a high risk of bleeding and must be carefully observed in the XAPASS as required by the Japanese health authority. Among the 11 308 patients enrolled in the XAPASS, 19.5% had a body weight of ≤50 kg and 48.7% had age of ≥75 years ( Table 1 ).
As shown in Figure 4 , 1641 patients (14.5%) had a body weight of ≤50 kg and age of ≥75 years. events per 100 patient-years in the ROCKET AF on-treatment population) and an incidence rate of major bleeding of 2.1 events per 100 patient-years, which is lower than that in the ROCKET AF (3.6 events per 100 patient-years). 11 Other ongoing noninterventional registries also provide real-world data on the effectiveness and safety of rivaroxaban, including the Global Anticoagulant Registry in the FIELD (GARFIELD)-AF, 12 Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT)-AF, 13 and the Dresden NOAC Registry. with preserved renal function) was received by 36% of the 640 patients who had moderate or severe renal impairment. 11 Initial analysis of the XAPASS also showed that treatment was started at a lower rivaroxaban dosage of 10 mg od in 252 (50.8%) of 496 patients whose CrCl was ≥50 mL/min. 15 The effects of these nonrecommended uses of rivaroxaban on safety and effectiveness outcomes will be reported. Treatment persistence with rivaroxaban will also be revealed in the XAPASS. Treatment persistence is a major concern in stroke prevention because discontinuation of anticoagulation therapy affects the stroke risk in patients with AF. 16 Persistence with rivaroxaban in the XANTUS was 80% at 1 year. 11 This is higher than in recent US studies 17, 18 but in line with the Dresden NOAC Registry, in which discontinuations of approximately 15% were recorded in the first year. | 173 low-and high-risk patients, such as those with a CHADS 2 score of 0 or 1, weighing ≤50 kg, and age of ≥75 years. These data will supplement those from clinical trials, further clarifying optimal rivaroxaban use in Japanese patients, and dissemination of the XAPASS findings to clinical settings will be recommended.
| CONCLUSIONS
The XAPASS provides practical information for the optimum use of rivaroxaban for stroke prevention in Japanese patients with AF in real-world clinical settings and supplements the findings of the J-ROCKET AF.
